Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...

Pharmacogenetics is the study of how individuals' genetic (inherited) make-up can affect their response to a medicine. This may be in terms of good or bad effects. A test (e.g., blood test ...

Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

The Mayo Clinic (MN, USA) is routinely offering pharmacogenetic testing of cytochrome P450s to help pinpoint genetic factors that influence a patient's response to certain antidepressants.

Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...

genetic testing, and personalized medicine, making it a dominant technology in the genomics market. The increasing demand for ...

BillionToOne, a next-generation molecular diagnostics company, announces three new executive appointments to support its expanding prenatal screening and oncology diagnostics business. Judy Wong joins ...

DoH experts will share key updates on the Emirati Genome Program (EGP), and highlight its impact on disease prevention and early diagnosis ...

Report Ocean has published a new report on the Companion Diagnostics for Oncology Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The ...

A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...